Image used for representation purpose only. | Photo Credit: Reuters Generic drugmaker Lupin has received U.S. Food and Drug Administration (USFDA) tentative approval for Sugammadex injection. The USFDA has tentatively approved Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial as bioequivalent to Merck’s Bridion Injection, it said on Tuesday (March 31, 2026). The drug is indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery, the company said. Published – March 31, 2026 11:42 am IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation Tamil Nadu election: Vijay, TVK cadre booked for conducting roadshow in violation of poll code Watch: Israel passes controversial death penalty law for Palestinians